

IFW



ATTORNEY DOCKET NO.: 1276-8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Nilendu Sen et al.

Examiner: Not Yet Assigned

Serial No.: 10/789,054

Group Art Unit: 1614

Filed: February 27, 2004

Date: August 31, 2004

For: PHARMACEUTICAL FORMULATION CONTAINING MUSCLE
RELAXANT AND COX-II INHIBITOR

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


Pursuant to Applicant(s) duty of disclosure, the information listed on the attached form PTO-1449 is brought to the attention of the Examiner. A copy of the foreign document and publication are enclosed.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art. The items listed are submitted in good faith, but are not intended to a substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist in identifying fields of search and in making as full and complete a search as possible.

CERTIFICATION UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 31, 2004


Bridget Griffin

The filing of this supplemental information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).


The references were cited in an International Search Report issued in counterpart International Application No. PCT/IB2004/001184 received from the International Searching Authority, dated August 18, 2004. Applicants are submitting a copy of the International Search Report.

Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 04-1121. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17(i)(i) are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Information Disclosure Statement as required and charge Deposit Account No. 04-1121 therefor. TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.

The claims of the application as now presented are believed to be patentably distinguishable over the prior art and to be in condition for allowance.

Early and favorable consideration of the case is respectfully requested.

Respectfully submitted,

A handwritten signature in black ink, reading "Michael E. Carmen", written over a horizontal line.


Michael E. Carmen

Reg. No. 43,533

Attorney for Applicants

DILWORTH & BARRESE, LLP
333 Earle Ovington Blvd.
Uniondale, NY 11553
(516) 228-8484
(516) 228-8516 (fax)
MEC:bg

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
1276-8SERIAL NO.
10/789,054APPLICANTS
Nilendu Sen et al.FILING DATE
02/27/04GROUP ART UNIT
1614INFORMATION DISCLOSURE
STATEMENT OF APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		US 2002/0132005	09/19/02	Faour			
		US 2003/0049319	03/13/03	Sriwongjanya et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		1 110 543	06/27/01	EPO				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

			Conklin et al., "Intrathecal Ketorolac Enhances Antinociception from Clonidine", <u>Anesth. Analg.</u> , 96:191-194 (2003).

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.